


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Ascension Borgess Hospital</p> <p>2. 1521 Gull Rd. Kalamazoo, MI 49048</p>		<p>In accordance with letter dated July 19, 2024,</p>	<p>4. Expiration Date: December 31, 2037</p>
		<p>3. License No.: 21-12275-02 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02115 Reference No.: 030-35603/030-17349</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Gadolinium-153</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources (North American Scientific, Inc., Model 3601)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 1000 millicuries total</p> <p>D. Four sources; 250 millicuries per source and 1 curie total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For possession and storage only with intent to dispose.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-12275-02

Docket or Reference No.:

030-02115

030-35603/030-17349

Amendment No. 119

**CONDITIONS**

10. A. Licensed material listed in Item Nos. 6.A. through 6.C. (excluding PET materials) shall be used at the licensee's facilities located at 1521 Gull Rd., Kalamazoo, Michigan, 49048.
- B. Licensed material listed in Item Nos. 6.A. and 6.B. (excluding PET materials) may be used or stored at the licensee's facilities located at Ascension Borgess Heart Center, 1722 Shaffer St., Suite 1, Kalamazoo, Michigan, 49048, and Ascension Borgess Health Park, Battle Creek, 3035 Capital Ave., S.W., Battle Creek, Michigan 49015.
- C. Licensed material listed in Item Nos. 6.A. through 6.D. (excluding PET materials) may be used or stored at the licensee's facilities located at 555 Linn St., Allegan, Michigan, 49010.
11. The Radiation Safety Officer (RSO) for this license is Paul Jursinic, PhD.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users

Nora Dajani, MD

Srinivasan Dhatreecharan, MD

Saul Friedman, MD

Venu Gourineni, MD

Craig Phillip Greenberg, MD

John Gustafson, MD

Anthony King, MD

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.200

10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.200

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-12275-02

Docket or Reference No.:

030-02115

030-35603/030-17349

Amendment No. 119

Authorized Users

Robert J. LaPenna, MD

William LaPenna, M.D.

Wael Marashdeh, MD

Jeffrey J. McClure, MD

Andrew K. Moriarty, MD

Rabin Nouranifar, MD

Stephen L. Peck, MD

Aldo C. Ruffolo, MD

Yousef B.E. Schulz, MD

Paul D. Shreve, MD

Gregorio U. Tan, MD

Michael J. Todd, MD

Alicia Williams, MD

Material and Use

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit in 10 CFR 30.35(d) for which decommissioning financial assurance is required.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 21-12275-02

Docket or Reference No.:


030-02115

030-35603/030-17349

Amendment No. 119

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Letter dated May 3, 2022 (ML22140A155)
- B. Letter dated November 17, 2022, excluding all references to SIR-Spheres (ML22326A035)
- C. "Delegation of Authority" letter dated December 6, 2022 (ML22340A483)
- D. Letter dated January 8, 2024 (ML24019A150)
- E. Letter dated March 12, 2024 (ML24072A303)
- F. Letter dated June 4, 2024 (ML24163A120)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date: September 3, 2024

By: \_\_\_\_\_

Bryan A. Parker  
Region III